Functional Dyspepsia Treatment Trial

Dyspepsia and Other Specified Disorders of Function of Stomach Clinical Trial

— FDTT  

Official title:

Antidepressant Therapy for Functional Dyspepsia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00248651
• Other study ID #: 2021-05 (DK065713)
• Secondary ID: U01DK065713
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: November 3, 2005
• Last updated: June 26, 2014
• Start date: October 2006
• Est. completion date: July 2013

Study information

• Verified date: June 2014
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationCanada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Functional dyspepsia is a common gastrointestinal disorder. Symptoms can include stomach pain or discomfort, bloating, fullness after eating meals, and nausea. These symptoms often interfere with school and work, and weight loss may occur due to dietary restrictions.

The hypothesis of this study was that antidepressant therapy is more effective than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidity. The study also examined if antidepressant therapy reduces disability and improves quality of life in functional dyspepsia.

Description:

The aims of this study were to:

1. Determine whether antidepressant therapy is more efficacious than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidity. The investigators also planned to determine if antidepressant therapy reduces disability, improves quality of life and influences clinical response over 6 months after ceasing medication.

2. Determine if gastric emptying (motor dysfunction) and the nutrient drink test (a test that assesses gastric hypersensitivity and/or gastric accommodation) is altered by antidepressant therapy with a tricyclic or selective serotonin re-uptake inhibitors (SSRI), and whether subgroups with altered physiology are associated with treatment outcome.

Other known NCT identifiers

• NCT00275626

Recruitment information / eligibility

• Status: Completed
• Enrollment: 292
• Est. completion date: July 2013
• Est. primary completion date: July 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Normal esophagogastroduodenoscopy (EGD) (no esophagitis, Barrett's esophagus, cancer, erosions, or ulcer disease) within the past 5 years

• Diagnosis of functional dyspepsia

• Patients may have failed to adequately respond to antisecretory therapy in the past for functional dyspepsia to be suitable; a good response to antisecretory therapy, which remains first line therapy, suggests underlying gastroesophageal reflux disease (GERD).

Exclusion Criteria:

• Any documented history of endoscopic esophagitis, or predominant heartburn or acid regurgitation, or these symptoms two or more times per week in the prior year, to exclude GERD.

• Those who have had an adequate response to antisecretory therapy according to the physician interview, to exclude patients with disease easy to control with first line therapy or misdiagnosed GERD.

• Any documented peptic ulcer disease.

• Regular use of non-steroidal anti-inflammatory drugs (except long term low dose aspirin = 325 mg / day)

• Subjects undergoing psychiatric treatment, having a current history of drug or alcohol abuse, or currently taking psychotropic medication for depression or psychosis, or eating disorders

• A history of abdominal surgery except appendectomy, cholecystectomy or hysterectomy, tubal ligations, bladder slings, and vasectomies

• Subjects with concurrent major physical illness (including cardiac or liver disease, diabetes, inflammatory bowel disease, glaucoma, urinary retention, active thyroid disease, vasculitis, lactose intolerance explaining symptoms)

• Subjects whose literacy skills are insufficient to complete self report questionnaires.

• Pregnancy, or refusal to apply adequate contraceptive measures during the trial

• Subjects currently on antidepressant therapy will be excluded.

• Patients who score 11 or greater on the 7 questions related to depression of the Hospital Anxiety Depression Scale will be excluded. These patients will be encouraged to get follow up for depression.

• All eligible patients over age 50 will have an EKG before randomization. Those found to have significant arrhythmias, conduction defects or a previous myocardial infarction on EKG will be excluded. Anyone with QT prolongation will be excluded.

The following concomitant medications will be prohibited during the trial:

• Systemically acting cholinergics and anticholinergics (atropine, didinium bromide, propantheline)

• Prokinetics (e.g., metoclopramide, tegaserod)

• Macrolide antibiotics (e.g., erythromycin, azithromycin)

• Aspirin (> 325 mg/day)

• Spasmolytics (e.g., dicyclomine)

• Antidepressants other than study medications

• Serotonin enhancing drugs: monamine oxidase inhibitors, anticonvulsants, dextromethorphan.

Participants will be instructed to avoid grapefruit/grapefruit juice during the trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dyspepsia
• Dyspepsia and Other Specified Disorders of Function of Stomach
• Stomach Diseases

Intervention

Drug:
• Amitriptyline
25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks. The drug will be provided in blister packs.
• Escitalopram
10 mg tablets by mouth at bedtime for 12 weeks. The drug will be provided in blister packs.
• Placebo
Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.

Locations

Country	Name	City	State
Canada	McMaster University Centre	Hamilton	Ontario
United States	Northwestern University Chicago	Chicago	Illinois
United States	Baylor College of Medicine	Houston	Texas
United States	Mayo Clinic Jacksonville	Jacksonville	Florida
United States	Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire
United States	Mayo Clinic	Rochester	Minnesota
United States	Saint Louis University School of Medicine	Saint Louis	Missouri
United States	Mayo Clinic	Scottsdale	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment	The first two weeks of treatment were excluded to allow for establishment of steady state drug levels.	3 weeks through 12 weeks	No
Secondary	Gastric Emptying Half-Time (T1/2)	The time for half of the ingested solids or liquids to leave the stomach.	12 weeks	No
Secondary	Maximum Tolerated Volume by Nutrient Drink Test	The nutrient drink test for meal-induced satiety had subjects drink 120 ml of ENSURE every four minutes. Satiety scores were measured on a scale graded 0-5 (1, no symptoms; 5, maximum satiety). When a score of 5 was reached, the maximum tolerated volume intake was measured. Abnormal satiety was defined as inability to consume > 800 ml of Ensure.	12 weeks	No
Secondary	Dyspepsia-Specific Quality of Life	The Nepean Dyspepsia Index (NDI) assessed quality of life. NDI scores are summarized into overall quality of life and 5 subscales: Interference, Knowledge/Control, Eating/Drinking, Sleep Disturbance, Work/Study. The scale consists of 25 items, yielding 5 sub-scales. Range 0-100, higher numbers indicate a greater quality of life.	12 Weeks	No